US Drug Recall Register
Class III · Low risk Terminated Initiated Sep 13, 2016 (10 years ago)

mitoXANTRONE Injection USP

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications: potential failure to meet the specification for Impurity D throughout shelf-life.

What was recalled

mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01.

Recalling firm
Teva Pharmaceuticals USA
NDC code
0703-4685-01
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0095-2017

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Mitoxantrone recalls

See all
Class III · Low risk Terminated

mitoXANTRONE Injection USP

Reason Failed Impurities/Degradation Specifications: High out of specification results for Impurity D.

Teva North America NDC 0703-4685-01 D-1451-2016
Class I · High risk Terminated

MitoXANTRONE Injection

Reason Failed Stability Specifications: Product is subpotent and has out of specification known and unknown impurities.

Hospira Inc. D-0433-2015